Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
Aminoacyltransferases
/ antagonists & inhibitors
Animals
Antigens, Differentiation
/ metabolism
CD47 Antigen
/ metabolism
Cell Line, Tumor
Cell Membrane
/ metabolism
Humans
Immunotherapy
Mice, Transgenic
Neoplasms
/ immunology
Opsonin Proteins
/ metabolism
Pyrrolidonecarboxylic Acid
/ metabolism
Receptors, Immunologic
/ metabolism
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
11
07
2018
accepted:
14
01
2019
pubmed:
6
3
2019
medline:
11
5
2019
entrez:
6
3
2019
Statut:
ppublish
Résumé
Cancer cells can evade immune surveillance through the expression of inhibitory ligands that bind their cognate receptors on immune effector cells. Expression of programmed death ligand 1 in tumor microenvironments is a major immune checkpoint for tumor-specific T cell responses as it binds to programmed cell death protein-1 on activated and dysfunctional T cells
Identifiants
pubmed: 30833751
doi: 10.1038/s41591-019-0356-z
pii: 10.1038/s41591-019-0356-z
pmc: PMC7025889
mid: EMS81308
doi:
Substances chimiques
Antigens, Differentiation
0
CD47 Antigen
0
Opsonin Proteins
0
Receptors, Immunologic
0
SIRPA protein, human
0
Aminoacyltransferases
EC 2.3.2.-
glutaminyl-peptide cyclotransferase
EC 2.3.2.5
Pyrrolidonecarboxylic Acid
SZB83O1W42
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-619Subventions
Organisme : European Research Council
ID : 742259
Pays : International
Références
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4–328rv4 (2016).
doi: 10.1126/scitranslmed.aad7118
Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).
doi: 10.1016/j.cell.2009.05.046
Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286–299 (2009).
doi: 10.1016/j.cell.2009.05.045
Weiskopf, K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur. J. Cancer 76, 100–109 (2017).
doi: 10.1016/j.ejca.2017.02.013
Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662–6667 (2012).
doi: 10.1073/pnas.1121623109
Matlung, H. L., Szilagyi, K., Barclay, N. A. & van den Berg, T. K. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol. Rev. 276, 145–164 (2017).
doi: 10.1111/imr.12527
Zhao, X. W. et al. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl Acad. Sci. USA 108, 18342–18347 (2011).
doi: 10.1073/pnas.1106550108
Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94–63ra94 (2010).
doi: 10.1126/scitranslmed.3001375
Chen, J. et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544, 493–497 (2017).
doi: 10.1038/nature22076
Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699–713 (2010).
doi: 10.1016/j.cell.2010.07.044
Weiskopf, K. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).
doi: 10.1126/science.1238856
Ring, N. G. et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc. Natl Acad. Sci. USA 114, E10578–E10585 (2017).
doi: 10.1073/pnas.1710877114
Advani, R. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
doi: 10.1056/NEJMoa1807315
Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227–231 (2016).
doi: 10.1126/science.aac9935
Seiffert, M. et al. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94, 3633–3643 (1999).
pubmed: 10572074
Cynis, H. et al. Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. J. Mol. Biol. 379, 966–980 (2008).
doi: 10.1016/j.jmb.2008.03.078
Schilling, S. et al. Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. J. Biol. Chem. 278, 49773–49779 (2003).
doi: 10.1074/jbc.M309077200
Stephan, A. et al. Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics. FEBS. J. 276, 6522–6536 (2009).
doi: 10.1111/j.1742-4658.2009.07337.x
Jimenez-Sanchez, M. et al. siRNA screen identifies QPCT as a druggable target for Huntington’s disease. Nat. Chem. Biol. 11, 347–354 (2015).
doi: 10.1038/nchembio.1790
Saido, T. C. et al. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 14, 457–466 (1995).
doi: 10.1016/0896-6273(95)90301-1
Tekirian, T. L., Yang, A. Y., Glabe, C. & Geddes, J. W. Toxicity of pyroglutaminated amyloid β-peptides 3(pE)-40 and -42 is similar to that of Aβ1-40 and -42. J. Neurochem 73, 1584–1589 (2002).
doi: 10.1046/j.1471-4159.1999.0731584.x
Russo, C. et al. Pyroglutamate-modified amyloid β-peptides - AβN3(pE) - strongly affect cultured neuron and astrocyte survival. J. Neurochem. 82, 1480–1489 (2002).
doi: 10.1046/j.1471-4159.2002.01107.x
Hatherley, D. et al. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol. Cell 31, 266–277 (2008).
doi: 10.1016/j.molcel.2008.05.026
Ho, C. C. M. et al. ‘Velcro’ engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J. Biol. Chem. 290, 12650–12663 (2015).
doi: 10.1074/jbc.M115.648220
Brooke, G., Holbrook, J. D., Brown, M. H. & Barclay, A. N. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J. Immunol. 173, 2562–2570 (2004).
doi: 10.4049/jimmunol.173.4.2562
Huang, K.-F., Wang, Y.-R., Chang, E.-C., Chou, T.-L. & Wang, A. H.-J. A conserved hydrogen-bond network in the catalytic centre of animal glutaminyl cyclases is critical for catalysis. Biochem. J. 411, 181–190 (2008).
doi: 10.1042/BJ20071073
Grizenkova, J. et al. Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice. Proc. Natl Acad. Sci. USA 109, 13722–13727 (2012).
doi: 10.1073/pnas.1208917109
Schilling, S. et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology. Nat. Med. 14, 1106–1111 (2008).
doi: 10.1038/nm.1872
Hoffmann, T. et al. Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease-studies on relation to effective target occupancy. J. Pharmacol. Exp. Ther. 362, 119–130 (2017).
doi: 10.1124/jpet.117.240614
Lues, I. et al. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimers Dement. (NY) 1, 182–195 (2015).
Huang, K. F., Liu, Y. L., Cheng, W. J., Ko, T. P. & Wang, A. H. J. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc. Natl Acad. Sci. USA 102, 13117–13122 (2005).
doi: 10.1073/pnas.0504184102
Boross, P. et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol. Med. 5, 1213–1226 (2013).
doi: 10.1002/emmm.201201929
Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209–1215 (2015).
doi: 10.1038/nm.3931
Ingram, J. R. et al. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc. Natl Acad. Sci. USA 114, 10184–10189 (2017).
doi: 10.1073/pnas.1710776114
Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418 (2017).
doi: 10.1038/nature23270
Sockolosky, J. T. et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc. Natl Acad. Sci. USA 113, E2646–E2654 (2016).
doi: 10.1073/pnas.1604268113
Ansell, S. et al. A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood 128, 1812 (2016).
Scheltens, P. et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res. Ther. 10, 107 (2018).
doi: 10.1186/s13195-018-0431-6
Morty, R. E., Bulau, P., Pellé, R., Wilk, S. & Abe, K. Pyroglutamyl peptidase type I from Trypanosoma brucei: a new virulence factor from African trypanosomes that de-blocks regulatory peptides in the plasma of infected hosts. Biochem. J. 394, 635–645 (2006).
doi: 10.1042/BJ20051593
Gong, Q. et al. A ultrasensitive near-infrared fluorescent probe reveals pyroglutamate aminopeptidase 1 can be a new inflammatory cytokine. Adv. Sci. (Weinh) 5, 1700664 (2018).
doi: 10.1002/advs.201700664
Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092–1096 (2015).
doi: 10.1126/science.aac7557
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
doi: 10.1186/gb-2009-10-3-r25
Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340–343 (2011).
doi: 10.1038/nature10348
Bracke, M., Lammers, J. W., Coffer, P. J. & Koenderman, L. Cytokine-induced inside-out activation of FcalphaR (CD89) is mediated by a single serine residue (S263) in the intracellular domain of the receptor. Blood 97, 3478–3483 (2001).
doi: 10.1182/blood.V97.11.3478
Berkovits, B. D. & Mayr, C. Alternative 3’ UTRs act as scaffolds to regulate membrane protein localization. Nature 522, 363–367 (2015).
doi: 10.1038/nature14321
Lackner, D. H. et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat. Commun. 6, 10237 (2015).
doi: 10.1038/ncomms10237
Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168–e168 (2014).
doi: 10.1093/nar/gku936
Neefjes, J. J., Breur-Vriesendorp, B. S., van Seventer, G. A., Iványi, P. & Ploegh, H. L. An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. Hum. Immunol. 16, 169–181 (1986).
doi: 10.1016/0198-8859(86)90046-7
Kuijpers, T. W. et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 78, 1105–1111 (1991).
pubmed: 1907873
Brandsma, A. M. et al. Simultaneous targeting of FcγRs and FcαRI enhances tumor cell killing. Cancer Immunol. Res. 3, 1316–1324 (2015).
doi: 10.1158/2326-6066.CIR-15-0099-T
Meyer, S. et al. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. Mabs 8, 87–98 (2016).
doi: 10.1080/19420862.2015.1106658
de Haij, S. et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 70, 3209–3217 (2010).
doi: 10.1158/0008-5472.CAN-09-4109
Gee, M. H. et al. Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes. Cell 172, 549–563.e16 (2018).
doi: 10.1016/j.cell.2017.11.043
Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520–526 (2009).
doi: 10.1038/nmeth.1345